Truist Financial Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)
BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Truist Financial in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $155.00 price objective on the stock, up from their previous price objective of $151.00. Truist Financial’s price objective suggests a potential upside of 39.46% […]
BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Truist Financial in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $155.00 price objective on the stock, up from their previous price objective of $151.00. Truist Financial’s price objective suggests a potential upside of 39.46% […]
